RESULTS OF RESISTANT PROLIFERATIVE LUPUS NEPHRITIS TREATMENT WITH CYCLOSPORINE A

Sheikholeslami, M and Javadzadegan, H and Hajialilo, M and Rasi Hashemi, S.S and Gadakchi, L and Khabbazi, A.R (2016) RESULTS OF RESISTANT PROLIFERATIVE LUPUS NEPHRITIS TREATMENT WITH CYCLOSPORINE A. The Journal of Urmia University of Medical Sciences, Vol. 27(2), May 2016, 27 (2). pp. 123-129.

Preview

Text 5.pdf Download (247kB) | Preview

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by various autoantibodies formation and immune complex deposition in various organs. Lupus nephritis is a common and severe manifestation of SLE that can lead to end stage renal disease and death. The aim of this study was to evaluate the long-term efficacy of cyclosporine A in the treatment of resistant proliferative lupus nephritis. Materials & Methods: In a retrospective study, patients with proliferative lupus nephritis that were resistant to treatment with mycophenolate mofetil and/or cyclophosphamide and treated with cyclosporine A were entered to the study. They were evaluated according to the remission of the renal disease, SLE disease activity index, occurrence of end stage renal disease, mortality and side effects of treatment. Results: Twenty-five patients with biopsy proven proliferative lupus nephritis with the mean age of 30±6.9 years including 5 men (20%) and 20 women (80%) were studied. The follow up duration was 27.1±17.6 months. Proteinuria was decreased significantly during the treatment with CSA (p<0.001). Serum creatinine was stable and the changes were not significant. Partial or complete remission occurred in 60% and 32% of the patients, respectively. Prednisolone dose was reduced from 26.3 mg/d before treatment to 6.8 mg/d after treatment with CSA (P=0.001). The most common adverse event was dyspepsia. Conclusion: According to results of our study, CSA is effective in treatment of proliferative lupus nephritis

Actions (login required)

View Item